BioCardia, Inc.
BCDA
|
$0.363
-1.39%
-1.4%
62K
|
Health Technology
(0.0% 1d) (-4.7% 1m) (-81.8% 1y) (0.0% 2d) (0.0% 3d) (-6.6% 7d) (-10.27% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 9,752,910
http://www.biocardia.com
Sec Filling | Patents | 24 employees
(US) BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
cardiovascular brands msa
add to watch list Paper trade email alert is off
Press-releases
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: -6.94%
H: 6.41%
C: 4.36%
business year financial results
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: 3.35%
H: 1.27%
C: 1.27%
conference update financial results
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: 2.2%
H: 7.72%
C: -0.13%
partnership
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
Published: 2024-03-12 (Crawled : 11:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: 5.58%
H: 2.85%
C: -14.27%
approval cell cardiamp heart therapy study
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: 0.03%
H: 1.72%
C: -21.53%
biomarker positive cell cardiamp heart therapy results
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
Published: 2024-02-08 (Crawled : 12:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: -8.54%
H: 9.0%
C: -1.97%
fda approved cardiamp heart study
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
Published: 2024-01-31 (Crawled : 12:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: -0.08%
H: 15.6%
C: -5.58%
conference heart technology therapeutics
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
Published: 2024-01-03 (Crawled : 12:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: -3.77%
H: 12.85%
C: 6.68%
business update
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
Published: 2023-12-19 (Crawled : 12:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: -0.31%
H: 3.24%
C: 1.53%
bcda-03 first treatment heart trial
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
BCDA | $0.363 -1.39% -1.4% 62K
|
Health Technology
|
| O: 3.53%
H: 10.41%
C: 4.63%
device japan expected approval cardiamp heart medical
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10